News
Fintel on MSN7d
UBS Downgrades Sarepta Therapeutics (SRPT)
Fintel reports that on July 21, 2025, UBS downgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from Buy to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback